首頁 > 市場調查報告書 > 製藥

孤兒藥

市場調查報告書

商品編碼

1621957

α1抗胰蛋白酶缺乏症治療的全球市場規模:各治療種模式，診斷試驗，各流通管道，各地區，範圍及預測

Global Alpha 1 Antitrypsin Deficiency Treatment Market Size By Therapeutic Modality, By Diagnostics Tests, By Distribution Channel, By Geographic Scope And Forecast

出版日期: 2024年09月15日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

α1抗胰蛋白酶缺乏症治療的市場規模與預測

2023年α1-抗胰蛋白酶缺乏症治療市場規模為18.2億美元，預計2024年至2031年複合年增長率為9.41%，2031年達到35億美元。 Alpha-1抗胰蛋白酶缺乏症（AATD），也稱為遺傳性慢性阻塞性肺病（COPD），是一種顯著增加肺部及相關疾病易感性的遺傳性疾病。當一個人從父母那裡繼承了 α1 抗胰蛋白酶 (AAT) 基因的正常副本和受損副本或兩個副本時，就會發生這種疾病。患有這種遺傳缺陷的人產生足夠的 α-1 抗胰蛋白酶的能力較低，α-1 抗胰蛋白酶是一種重要的蛋白質，可以保護肺部免受酵素活性造成的傷害。因此，他們更有可能患上嚴重的肺部疾病，包括慢性阻塞性肺病。在各國政府的指導方針和建議的推動下，治療 α-1 抗胰蛋白酶缺乏症的重要性已受到廣泛關注。

這些指引強調需要早期診斷和適當的管理策略，以減少這種遺傳疾病對受影響個體健康的影響。

α1-抗胰蛋白酶缺乏症治療的全球市場動態

塑造全球 alpha-1 抗胰蛋白酶缺乏症治療市場的關鍵市場動態

主要市場驅動因子

增加研發活動以加速市場成長

由於研發 (R&D) 活動的增加，α-1 抗胰蛋白酶缺乏症 (AATD) 治療市場有望顯著成長。策略性公私夥伴關係為持續創新營造了良好的環境。這些合作對於開發治療 AATD 的新藥和先進醫療技術至關重要。

增加醫療基礎建設投資

醫療基礎設施投資也是推動 AATD 治療市場成長的關鍵因素之一。醫療保健支出的增加正在推動基礎設施的發展，特別是在發展中國家。這項擴張支持了新的先進醫療技術、設備和藥品的引進和部署，直接推動了對 AATD 治療的需求。 AATD 診斷和治療指南的出現、潛在管道產品的開發以及對 AATD 認識的提高正在推動對 AATD 治療藥物的需求。 AATD 的日益普及預計將在預測期內進一步提振市場成長前景。

病人支持組織的角色

患者權益團體和支持組織在 AATD 治療中發揮重要作用。這些組織倡導提高 AATD 患者的認識、確保研究經費並改善其獲得治療選擇的機會。他們的努力對醫療保健政策和決策過程產生了重大影響，為市場擴張做出了積極貢獻。透過為患者創造支持性環境並促進政策變化，這些倡導組織將確保滿足 AATD 患者的需求並進一步加速市場成長。

基因檢測的普及：

基因檢測、血液檢測和活檢檢測的日益普及對市場成長做出了重大貢獻。公營和私營部門旨在提高人們對 α-1 抗胰蛋白酶缺乏症 (AATD) 認識的努力也發揮著至關重要的作用。領先製造商建立的有組織的分銷網絡加強了這些努力，確保新療法有效地到達患者手中。對有效治療方法的需求不斷增加以及早期診斷方法的可用性不斷增加，正在對市場成長軌跡產生積極影響。

主要問題

研發成本上升：

與研發相關的高成本是市場成長的最大限制之一。開發新療法和醫療技術的財務負擔是進步的障礙，特別是對於資金不足的中小企業和發展中國家而言。

缺乏意識和基礎設施：

許多發展中國家和不發達國家嚴重缺乏有效診斷和治療 α-1 抗胰蛋白酶缺乏症 (AATD) 的意識和必要的基礎設施。知識和資源的缺乏導致診斷率低並阻礙市場擴張。

藥物核准緩慢且專利到期：

新藥和抑制劑的審批過程緩慢也是市場挑戰。進一步的障礙包括有限的血漿分離能力和越來越多的專利到期，從而減緩了新療法的出現。

因各種症狀而未能充分診斷：

儘管人們的認識不斷提高，但由於不同的臨床症狀和缺乏標準的篩檢方法，AATD 的診斷率仍然較低。由於公眾和醫療保健專業人員缺乏認識，這種診斷不足的情況更加嚴重，導致診斷和治療的延誤並阻礙市場成長。

有限的治療選擇：

儘管治療方法的開發正在取得進展，但可用的治療選擇仍然相對較少，特別是對於病情嚴重的患者或對現有治療沒有反應的患者。由於缺乏針對特定疾病途徑的有效藥物，許多患者的醫療需求得不到滿足，並限制了市場成長。

複雜的病理生理學：

AATD 受到遺傳、環境和免疫因素的複雜影響，使得開發具有最佳安全性和有效性的標靶治療藥物變得困難。需要進行廣泛的研究來了解這種疾病的潛在機制並確定適當的治療靶點，這減緩了新療法的開發和商業化。

醫療基礎設施方面的差異：

醫療保健基礎設施的差異，特別是在資源匱乏和服務不足的社區，限制了患者獲得診斷測試和專門治療的機會。這些阻礙因素包括醫療設施不足、缺乏訓練有素的人員以及向偏遠地區提供治療的後勤挑戰，阻礙了患者獲得治療和堅持治療。

主要趨勢

意識不斷提高：

公眾和醫療保健專業人員對 α-1 抗胰蛋白酶缺乏症 (AATD) 的認識顯著提高。這種認識的提升有助於早期診斷和及時開始治療。因此，需要治療的患者數量增加，推動了 AATD 藥物的需求。

診斷工具的擴充：

技術的進步正在促使更準確、更容易使用的 AATD 診斷工具的開發。諸如此類的改進工具可以實現早期發現和早期幹預，這對於有效管理 AATD 和預防併發症至關重要。

遠距醫療的角色日益增強：

遠距醫療平台在 AATD 的管理中發揮越來越重要的作用。這些平台改善了患者接觸專家、支持小組和教育資源的機會。遠距醫療有助於持續的照護和支持，特別是對於偏遠和服務欠缺地區的患者。

個人化醫療的興起：

個人化醫療的趨勢在 AATD 的治療中也變得越來越突出。事實證明，根據患者個別特徵、遺傳特徵和疾病嚴重程度量身訂做治療計劃更為有效。個人化醫療方法使患者能夠根據自己的病情接受最合適、最有效的治療。

日益關注新興市場：

發展中國家醫療基礎設施的改善和可支配收入的增加為 AATD 治療提供者帶來了新的機會。隨著這些市場的擴大，對 AATD 治療的需求可能會大幅成長。越來越多的公司瞄準這些新興市場，擴大進入範圍並尋求滲透市場。

Alpha 1 Antitrypsin Deficiency Treatment Market size was valued at USD 1.82 Billion in 2023 and is projected to reach USD 3.5 Billion by 2031, growing at a CAGR of 9.41% from 2024 to 2031. Alpha-1 Antitrypsin Deficiency (AATD), also known as genetic Chronic Obstructive Pulmonary Disease (COPD), is a hereditary condition that significantly increases susceptibility to lung and related diseases. This condition arises when an individual inherits either one normal and one damaged copy or two damaged copies of the alpha-1 antitrypsin (AAT) gene, which is received from each parent. Those with this genetic deficiency have a reduced ability to produce sufficient levels of alpha-1 antitrypsin, a protein essential for protecting the lungs from damage caused by enzyme activity. As a result, they are more prone to developing severe lung conditions, including COPD. The importance of treating alpha-1 antitrypsin deficiency has garnered considerable attention, driven by the guidelines and recommendations provided by governments across various countries.

These guidelines emphasize the need for early diagnosis and appropriate management strategies to mitigate the impact of this genetic disorder on affected individuals' health.

Global Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics

The key market dynamics that are shaping the global alpha 1 antitrypsin deficiency treatment market include:

Key Market Drivers

Increasing Research and Development Activities to Accelerate Market Growth

: The alpha-1 antitrypsin deficiency (AATD) treatment market is poised for significant growth, driven by an upsurge in research and development (R&D) activities. Strategic collaborations between public and private entities are fostering a robust environment for continuous innovation. These collaborations are crucial in the development of new pharmaceuticals and advanced medical technologies aimed at treating AATD.

Increasing Healthcare Infrastructure Investment

: Investment in healthcare infrastructure is another critical factor driving the growth of the AATD treatment market. Increased healthcare spending is facilitating infrastructure improvements, particularly in developing countries. This expansion supports the adoption and deployment of new and advanced medical technologies, equipment, and pharmaceuticals, directly boosting the demand for AATD therapies. The emerging guidelines for the diagnosis and treatment of the condition, the development of potential pipeline products, and rising awareness about AATD. The increasing prevalence of AATD is expected to further enhance the market's growth prospects during the forecast period.

Role of Patient Advocacy Groups

: Patient advocacy groups and support organizations play a crucial role in the AATD treatment landscape. These groups are instrumental in raising awareness, securing funding for research, and advocating for improved access to treatment options for individuals with AATD. Their efforts significantly influence healthcare policies and decision-making processes, contributing positively to market expansion. By fostering a supportive environment for patients and driving policy changes, these advocacy groups ensure that the needs of those with AATD are met, further accelerating market growth.

Increasing Prevalence of Genetic Testing:

The increasing prevalence of genetic testing, blood tests, and biopsy tests is significantly contributing to the market's growth. Public and private sector initiatives aimed at raising awareness about Alpha-1 Antitrypsin Deficiency (AATD) are also playing a pivotal role. These efforts are bolstered by a well-organized distribution network established by leading manufacturers, ensuring that new treatments reach patients efficiently. The growing demand for effective medications and the expanding use of early diagnostic methods are positively impacting the market's growth trajectory.

Key Challenges

High R&D Costs:

The significant expenses associated with research and development pose one of the most substantial limitations to the market's growth. The financial burden of developing new treatments and medical technologies can stymie progress, particularly for smaller companies and developing nations lacking adequate funding.

Lack of Awareness and Infrastructure:

In many developing and underdeveloped countries, there is a notable deficiency in both the awareness and the necessary infrastructure to effectively diagnose and treat Alpha-1 Antitrypsin Deficiency (AATD). This lack of knowledge and resources leads to sluggish diagnostic rates, further hampering market expansion.

Slow Medication Approval and Patent Expirations:

The market is also challenged by the slow approval process for new medications and inhibitors. Additionally, the limited capacity for plasma fractionation and the increasing number of patent expirations present further obstacles, delaying the availability of new treatments.

Underdiagnosis Due to Variable Presentation:

Despite growing awareness, AATD remains underdiagnosed because of its variable clinical presentation and the absence of standard screening procedures. This underdiagnosis, exacerbated by a lack of awareness among both the general public and healthcare professionals, results in delayed diagnosis and treatment, hindering market growth.

Limited Treatment Options:

Although advancements in therapeutic development have been made, there are still relatively few treatment options available, particularly for patients with severe forms of the disease or those who do not respond well to existing treatments. This scarcity of effective medicines targeting specific disease pathways leaves many patients' medical needs unmet, restricting market growth.

Complex Disease Pathophysiology:

AATD involves a complex interplay of genetic, environmental, and immunological factors, making it challenging to develop targeted therapies with optimal safety and efficacy profiles. Extensive research is needed to understand the disease's underlying mechanisms and identify suitable therapeutic targets, which delays the development and commercialization of new treatments.

Healthcare Infrastructure Disparities:

Disparities in healthcare infrastructure, especially in resource-constrained regions and underserved communities, limit patients' access to diagnostic tests and specialized care. Inadequate healthcare facilities, a shortage of trained personnel, and logistical challenges in delivering treatments to remote areas contribute to these constraints, impeding patient access and adherence to therapy.

Key Trends

Growing Awareness:

There is a significant increase in both public and healthcare professional awareness regarding Alpha-1 Antitrypsin Deficiency (AATD). This heightened awareness is facilitating earlier diagnosis and prompt initiation of treatment. As a result, the patient pool requiring treatment is expanding, driving demand for AATD therapies.

Expanding Diagnostic Tools:

Technological advancements are leading to the development of more accurate and accessible diagnostic tools for AATD. These improved tools enable earlier identification and intervention, which is crucial for managing the disease effectively and preventing complications.

Growing Role of Telehealth:

Telehealth platforms are playing an increasingly important role in the management of AATD. These platforms improve patient access to specialists, support groups, and educational resources. Telehealth facilitates continuous care and support, especially for patients in remote or underserved areas.

Rise of Personalized Medicine:

The trend towards personalized medicine is becoming more prominent in the treatment of AATD. Tailoring treatment plans based on individual patient characteristics, genetic profiles, and disease severity is proving to be more effective. Personalized medicine approaches ensure that patients receive the most appropriate and effective therapies for their specific conditions.

Increased Focus on Emerging Markets:

The growing healthcare infrastructure and rising disposable incomes in developing countries present new opportunities for AATD treatment providers. As these markets expand, there is potential for significant growth in the demand for AATD therapies. Companies are increasingly targeting these emerging markets to broaden their reach and enhance market penetration.

Global Alpha 1 Antitrypsin Deficiency Treatment Market Regional Analysis

Here is a more detailed regional analysis of the global alpha 1 antitrypsin deficiency treatment market:

Asia Pacific

The Asia-Pacific region significantly dominates the global alpha-1 antitrypsin deficiency (AATD) treatment market. This dominance is due to its vast patient population and an expanding elderly demographic.

This region is expected to experience substantial growth due to several key factors. The burgeoning medical tourism industry in Asia-Pacific, spurred by the availability of advanced medical treatments at competitive prices, is attracting patients globally. This influx boosts the demand for sophisticated healthcare services, including AATD treatments.

Rising healthcare expenditure across Asia-Pacific countries is also contributing to market growth. Increased investment in healthcare infrastructure and services reflects a broader commitment to enhancing medical care and accessibility.

In addition, regional governments are prioritizing the development of healthcare infrastructure, with significant initiatives aimed at advancing the biotechnology, agriculture, and pharmacology sectors.

These initiatives not only improve the overall healthcare landscape but also promote the development and availability of advanced AATD therapies, further driving market expansion in the region.

North America

North America is anticipated to witness the fastest growth in the global alpha-1 antitrypsin deficiency (AATD) treatment market during the forecast period.

This rapid growth is primarily driven by several factors, including the increasing number of clinical trials focused on genetic disease therapeutics.

These trials are pivotal in advancing treatment options and improving patient outcomes, thereby solidifying the region's leadership in the market.

The region benefits from a well-established healthcare infrastructure, characterized by the availability of qualified specialists and advanced genetic testing equipment. These resources collectively facilitate superior diagnosis and treatment of AATD, ensuring that patients receive timely and accurate care.

The presence of cutting-edge medical facilities and a robust healthcare system further enhances the region's capability to manage AATD effectively.

High healthcare spending and favorable reimbursement policies are additional factors that support the market's growth in North America. These financial aspects make it easier for patients to access necessary treatments without facing prohibitive costs.

Insurance coverage and reimbursement plans also incentivize healthcare providers to adopt and recommend advanced AATD therapies, thereby increasing the overall treatment rate.

Significant investments by major players in the region are fueling research and development activities, leading to improved diagnostics and a higher rate of identification of AATD cases. These investments are crucial in driving innovation and the development of new, more effective treatments.

Pharmaceutical companies and biotech firms are actively engaged in exploring novel therapies, including gene therapies and advanced augmentation therapies, which hold promise for better management of AATD.

Furthermore, the rising prevalence of respiratory disorders in North America contributes to the market's substantial share. As respiratory conditions often exacerbate the symptoms of AATD, there is a growing need for effective treatment solutions.

The increasing incidence of conditions such as Chronic Obstructive Pulmonary Disease (COPD) highlights the importance of addressing AATD comprehensively.

Europe

Europe is anticipated to show lucrative growth in the global alpha 1 antitrypsin deficiency treatment market during the forecast period.

Increasing research and development initiatives aimed at enhancing treatment for various respiratory disorders.

Growing consumer awareness about AATD and its therapeutic options is driving demand. Furthermore, the rise in the elderly population, more susceptible to respiratory diseases, is positively influencing the market dynamics.

Europe's focus on improving healthcare services and its commitment to addressing respiratory health issues make it a key player in the global AATD treatment market.

Europe holds the position of the second-largest market for the alpha-1 antitrypsin deficiency (AATD) industry, attributed to its abundance of qualified specialists and access to modern genetic testing equipment. This well-established infrastructure facilitates early and accurate diagnosis, leading to effective management and treatment of AATD.

Looking ahead, Europe is poised for rapid development and is expected to grow at the fastest rate throughout the forecast period.

The expanding patient pool, due in part to better diagnostic capabilities and increasing awareness of AATD, is contributing significantly to market expansion.

In Addition, the region benefits from robust government backing, with numerous initiatives aimed at improving healthcare infrastructure and supporting research and development in genetic and respiratory disorders.

Government policies and funding are playing a crucial role in advancing the AATD market in Europe. These measures include support for public health campaigns to raise awareness about AATD, investments in state-of-the-art medical facilities, and incentives for pharmaceutical companies to develop innovative treatments.

Furthermore, collaborations between the public and private sectors are enhancing research efforts, leading to the development of new and more effective therapies.

The growing geriatric population in Europe, which is more prone to respiratory conditions, also fuels the demand for AATD treatments. As a result, the region is witnessing an increase in the adoption of advanced medical technologies and therapies designed to improve patient outcomes.

With these favorable conditions, Europe is set to solidify its position as a key player in the global AATD treatment market, driving significant advancements and improvements in patient care.

Global Alpha 1 Antitrypsin Deficiency Treatment Market Segmentation Analysis

The Global Alpha 1 Antitrypsin Deficiency Treatment Market is segmented based on Therapeutic Modality, Diagnostics Test, Distribution Channel, And Geography.

Alpha 1 Antitrypsin Deficiency Treatment Market, By Therapeutic Modality

Augmentation Therapy
Bronchodilators Corticosteroids
Gene Therapy
Supportive Care

Based on Therapeutic Modality, the Global Alpha 1 Antitrypsin Deficiency Treatment Market is bifurcated into Augmentation Therapy, Bronchodilators Corticosteroids, Gene Therapy, and Supportive Care. Bronchodilators Corticosteroids segment showing significant growth in the global alpha 1 antitrypsin deficiency treatment market. The rise of the corticosteroid segment in the alpha-1 antitrypsin deficiency (AATD) market is primarily driven by the increasing prevalence of chronic illnesses, an aging population, and heightened Research and Development (R&D) spending. The global burden of chronic diseases is anticipated to escalate significantly in the coming years, further fueling the demand for corticosteroid therapies.

Alpha 1 Antitrypsin Deficiency Treatment Market, By Diagnostics Tests

Serological Tests
Genetic Testing
Imaging Studies

Based on Diagnostics Tests, the Global Alpha 1 Antitrypsin Deficiency Treatment Market is bifurcated into Serological Tests, Genetic Testing, and Imaging Studies. The genetic testing segment showing significant growth in the global alpha 1 antitrypsin deficiency treatment market owing to the accurate diagnosis of alpha-1 antitrypsin deficiency (AATD) is crucial as it ensures reliable identification of the condition, providing a definitive diagnosis. This precision extends to carrier identification, helping to detect individuals who carry the AATD gene but may not yet exhibit symptoms. Such early detection facilitates genetic counseling and intervention for potential offspring. Moreover, timely and accurate diagnosis allows for the early initiation of treatment, which can greatly enhance patient outcomes and improve the overall management of the disease.

Alpha 1 Antitrypsin Deficiency Treatment Market, By Distribution Channel

Hospitals
Specialty Clinics
Retail Pharmacies

Based on the Distribution Channel, the Global Alpha 1 Antitrypsin Deficiency Treatment Market is bifurcated into Hospitals, Specialty Clinics, and Retail Pharmacies. The hospital segment showing significant growth in the global alpha 1 antitrypsin deficiency treatment market driven by the increasing patient preference for hospital admissions for treatment. The desire for comprehensive care and access to advanced medical resources. Additionally, the presence of highly skilled medical personnel enhances the quality of treatment, contributing to a growing market share in the coming years.

Alpha 1 Antitrypsin Deficiency Treatment Market, By Geography

North America
Europe
Asia Pacific
Rest of the World

Based on Geography, the Global Alpha 1 Antitrypsin Deficiency Treatment Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. The Asia-Pacific region significantly dominates the global alpha-1 antitrypsin deficiency (AATD) treatment market. The vast patient population and an expanding elderly demographic are the reason likely to enable the region hold major share in the market. This region is expected to experience substantial growth due to several key factors. The burgeoning medical tourism industry in Asia-Pacific, spurred by the availability of advanced medical treatments at competitive prices, is attracting patients globally. This influx boosts the demand for sophisticated healthcare services, including AATD treatments. Rising healthcare expenditure across Asia-Pacific countries is also contributing to market growth. Increased investment in healthcare infrastructure and services reflects a broader commitment to enhancing medical care and accessibility.

Key Players

The "Global Alpha 1 Antitrypsin Deficiency Treatment Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as
Takeda Pharmaceutical Company Limited, Alexion Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals Incorporated, Boehringer Ingelheim GmbH, United Therapeutics Corporation, Paramount Biosciences Inc., Protalix BioTherapeutics, Inc., Galecto, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Alpha 1 Antitrypsin Deficiency Treatment Market Recent Developments
In October 2022, Kamada Ltd., a vertically integrated global biopharmaceutical company focused on specialty plasma-derived therapeutics, announced that it had been awarded a three-year extension of an existing tender from the Canadian Blood Services (CBS) for the supply of four IgG products, CYTOGAM(R), HEPAGAM(R), VARIZIG(R), and WINRHO(R) SDF, for an estimated total value of US$ 22 million. This award ensures that such things will continue to be offered on the Canadian market.
In May 2022, Boehringer Ingelheim announced that ArisGlobal had bought their digital invention, BRASS. This data insights engine will be integrated into ArisGlobal's LifeSphere(R) technology platform as LifeSphere Clarity, and it will play an important role in driving industry-wide improvement in pharmacovigilance and patient safety.